At a Glance
Sofinnova Investments is one of the oldest and most established life sciences venture capital firms, founded in 1972 with roots in France before expanding to the United States. The firm has built a reputation as a premier investor in biotechnology, pharmaceuticals, and medical devices, with a particular focus on companies developing innovative therapeutics for serious medical conditions. Sofinnova's investment approach combines deep scientific expertise with extensive industry networks, allowing them to identify and support breakthrough technologies from early research through commercialization. The firm maintains offices in both San Francisco and Paris, providing unique trans-Atlantic capabilities for portfolio companies seeking global market access. Led by experienced partners with backgrounds in science, medicine, and business, Sofinnova has been involved in numerous successful exits including IPOs and strategic acquisitions. What distinguishes the firm is its hands-on approach to portfolio support, often taking active roles in helping companies navigate regulatory pathways, build management teams, and establish strategic partnerships with pharmaceutical giants.
“Invests in life sciences companies developing breakthrough therapeutics, medical devices, and healthcare technologies with strong scientific foundations and commercial potential.”
Sofinnova Investments primarily invests at the Seed, Series A, Series B+ stages. This means they focus on companies that are building their initial product and finding product-market fit.
Sofinnova Investments is headquartered in San Francisco, CA. Many of their portfolio companies are also based in this region, though they invest across geographies.
Sofinnova Investments focuses on investments in Biotech, Digital Health. Their portfolio reflects deep expertise and networks within these sectors.
Sofinnova Investments manages approximately $2.8B in assets under management (AUM) across their funds.